PRESS RELEASE
News
-
-
-
-
-
PRESS RELEASE
Communiqué de presse : La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1
Sanofi's SAR446268 therapy granted fast track designation by US FDA for treating non-congenital myotonic dystrophy type 1. Innovative gene therapy aims to address unmet medical need -
PRESS RELEASE
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 granted US fast track designation for non-congenital myotonic dystrophy type 1. AAV gene therapy aims to silence DMPK expression, addressing symptoms and filling unmet need -
-
-
PRESS RELEASE
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sanofi's brivekimig shows positive results in phase 2a study for hidradenitis suppurativa, presenting clinically meaningful improvements in primary and secondary endpoints in biologic-naïve patients -
PRESS RELEASE
Sanofi: Disclosure of trading in own shares
